Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.62 USD
+0.14 (3.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.61 -0.01 (-0.22%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VNDA 4.62 +0.14(3.13%)
Will VNDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
Other News for VNDA
Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Shareholder Capital delivers letter to board of Vanda Pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZĀ® ANDA Litigation
US Supreme Court reportedly declines to hear Vanda patent case